I have not looked at the data closely and I am not sure how much better Motavizumab is compared to Synagis. My feeing is that it is analogous to EPO/Aranesp. I think that MEDI's RSV vaccine has a better chance of being a game changer.
With regards to RSV, what is your read of ALNY's RNAi compound? The quantitative knock down of viral levels seems encouraging. Plus the compound is designed to treat active infection rather than be preventative.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.